MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

L⁻⁷79450

CAS No. : 303727-31-3

MCE 国际站：L⁻⁷79450

产品活性：L⁻⁷79450 是一种有效的选择性 B-Raf 抑制剂，K_d 为 2.4 nM。

研究领域：MAPK/ERK Pathway | Autophagy

作用靶点：Raf | Autophagy

In Vitro: L⁻⁷79450 (L⁻⁷79,450) shows a high degree of specificity towards Raf. The only other tested kinase inhibited is p38MAPK, which has a kinase domain structurally related to Raf. L⁻⁷79450 inhibits anchorage-independent growth of human tumor lines at doses ranging from 0.3 to 2 µM. The effects of L⁻⁷79450 (L⁻⁷79,450) on TRAIL sensitivity are investigated here in melanoma cell lines with high TRAIL sensitivity (A-375 and SK-Mel-147), moderate sensitivity (Mel-HO, SK-Mel-13, and SK-Mel-28), and permanent resistance (MeWo, Mel-2a, and SK-Mel-103), as well as in TRAIL-selected cell lines with acquired resistance (A-375-TS and Mel-HO-TS). Despite only moderate direct effects of L⁻⁷79450 on apoptosis, it strongly enhances TRAIL-induced apoptosis in sensitive melanoma cells and overrules TRAIL resistance in Mel-2a, SK-Mel-103, A-375-TS, and Mel-HO-TS. At 24 hours, 16-35% apoptosis induction is obtained.

相关产品：Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Anti-Cancer Compound Library | CNS-Penetrant Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Oxygen Sensing Compound Library | Ferroptosis Compound Library | Glutamine Metabolism Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Doramapimod | GW 5074 | Ro 5126766 | AZ 628 | GDC-0879 | ZM 336372 | Agerafenib | Raf inhibitor 1 | AZ304 | MCP110 | Sorafenib (D3) | Raf inhibitor 2

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。